TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03658746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline)
Description: Patients will receive a 14-day quadruple therapy for the H.pylori eradication. The regimen contains one proton pump inhibitor, colloidal bismuth pectin and two sensitive antibiotics determined by antimicrobial susceptibility test. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: one proton pump inhibitor, colloidal bismuth pectin
Description: All patients need these two drugs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: one proton pump inhibitor, colloidal bismuth pectin
Description: All patients need these two drugs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: two antibiotics based on personal medication history(amoxicillin,levofloxacin, furazolidone)
Description: Patients will receive a 14-day quadruple therapy according to personal medication history for helicobacter pylori eradication. The regimen contains one proton pump inhibitor, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient hasn't been treated with levofloxacin previously, he will be treated with amoxicillin and levofloxacin. Otherwise, he will be treated with amoxicillin and furazolidone.
Study: NCT02513420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perineal muscle training
Description: It is a combination of perineal massage and Kegel exercises.
Study: NCT04184440

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cyclocarya paliurus extract
Description: The participants are divided randomly into three groups，one of which are asked to Cyclocarya paliurus extract for three months .

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cyclocarya paliurus compounds
Description: The participants are divided randomly into three groups，one of which are asked to take Cyclocarya paliurus compounds for three months .

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The participants are divided randomly into three groups，one of which are asked to take placebo for three months .
Study: NCT00893126

Intervention type: PROCEDURE
Intervention: CCTA Scan (Coronary CT Angiogram)
Description: CCTA scan will be performed to study and evaluate the prevalence and severity of coronary artery disease (CAD).

Intervention type: PROCEDURE
Intervention: CCTA Scan (Coronary CT Angiogram)
Description: CCTA scan will be performed to study and evaluate the prevalence and severity of coronary artery disease (CAD).
Study: NCT02332109

Intervention type: DEVICE
Intervention: ODM 5
Description: ODM 5 is a CE-certified, preservative-free, hyperosmolar ophthalmological solution containing 5% sodium chloride and 0.15% sodium hyaluronate recommended for the reduction of corneal edema. The patient will use ODM 5 on a daily basis in accordance with the instructions for use and as recommended by the investigator over a period of 8 weeks.
Study: NCT03270904

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moleculight i:X™ fluorescence imaging
Description: Moleculight i:X™ is a hand held device that emits violet blue light. By controlling distance from the wound and ambient light, Moleculight i:X™ identifies bacteria above a pre-determined concentration by identifying natural fluorescence in the bacteria cell wall.
Study: NCT00646061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buscopan
Study: NCT03656978

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dynamic
Description: Use the according methods in dynamic arm descriptions.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Regular-triangle
Description: Use the according methods in regular-triangle arm descriptions.
Study: NCT01969318

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo /Metformin
Description: Patients are administered oral tablets of placebo once daily and metformin 500 mg t.i.d for 2 weeks at run-in period.After randomized,patients will be administered the drugs too

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP2086(50 mg q.d.)/Metformin
Description: patients are administered oral placebo once daily and metformin 500 mg t.i.d for 2 weeks at the run-in period .After randomized ,patients will be administered SP2086 50 mg q.d. and 500 mg t.i.d for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP2086 (100 mg q.d.)/Metformin
Description: patients are administered oral placebo once daily and metformin 500 mg t.i.d for 2 weeks at the run-in period .After randomized ,patients will be administered SP2086 100 mg q.d. and 500 mg t.i.d for 12 weeks
Study: NCT01179451

Intervention type: DEVICE
Intervention: echocardiogram
Description: echocardiogram
Study: NCT00355056

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Will not receive the closure device, and will be treated with the current standard of care medical treatment. Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and simulate PFO closure procedure (sham procedure). Participants completing 1 year follow-up are eligible for PFO closure with the AMPLATZER PFO Occluder.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMPLATZER PFO Occluder
Description: Patients in this arm will receive the AMPLATZER PFO Occluder device
Study: NCT03184168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]lorlatinib
Description: Extemporaneously compounded oral solution of \[14C\]lorlatinib (approximately 100 mg/100 µCi)
Study: NCT02222623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: Glargine given as 100% total daily dose with breakfast. The initial dose will be calculated using the patient's weight or using their basal insulin doses prior to hospitalization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH
Description: NPH 2/3 of the total daily dose given with breakfast, 1/3 of the total daily dose given at bedtime. The initial dose is calculated using the patient's weight or using the basal insulin dose prior to hospitalization.
Study: NCT00361296

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: K562/GM-CSF cell vaccine
Study: NCT00826111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eszopiclone
Description: Subjects receive 10 mg escitalopram daily for four weeks and 10 or 20 mg for an additional six weeks. Subjects also receive 3 mg eszopiclone.
Study: NCT00391586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib will be administered for at least 2 cycles (6 weeks) and for a maximum of 8 months.~Upon progression or intolerance to erlotinib, standard of care platinum-based chemotherapy (per the choice of the treating physician) is administered every 3 weeks. Physicians can adjust dose, schedule, or supportive care to the benefit of the patient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Description: Intravenous chemotherapy combination per physician discretion every 3 weeks for at least 2 cycles
Study: NCT03281798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetoscopes
Description: Fetoscopes are telescopes developed for procedures involving fetal interventions and is inserted through the maternal abdomen.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fetal Cystoscopy
Description: A fetoscope will be inserted into the fetal bladder via the maternal abdomen and advanced into the fetal bladder outlet. Identified obstruction will be opened using laser.
Study: NCT01499355

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB023

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB023

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: titrated to a target daily dose of 2 g (1 g twice daily)
Study: NCT00826111

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive 10 mg of escitalopram daily for four weeks followed by 10 or 20 mg for an additional six weeks. Subjects also receive placebo for eszopiclone.
Study: NCT03996499

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stress echocardiography
Description: The course of the examination corresponds to the welcome of the patient, the search for contraindications and the performance of the stress ultrasound. During this stress ultrasound, the 3 indices (segmental kinetics, coronary reserve and myocardial perfusion) will be analyzed. The duration of the ultrasound is not lengthened (examination time: 20 minutes).~The evaluation of the myocardial perfusion is carried out thanks to the use of the flash, modality not being part of the usual care.~Indeed, during the examination, the power of the probe will be increased to evaluate the myocardial perfusion. The bubbles of the contrast medium are destroyed by applying a flash, that is to say a transient increase in the power of the ultrasonic beam. Systole after systole, on a recorded loop, the filling rate of the myocardium, which depends on the myocardial blood flow, is analyzed. The evaluation of the infusion is visual and qualitative.
Study: NCT03699436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrotherapy with Galvanic Current
Description: The experimental group will receive an electrotherapy treatment with galvanic current in their hands.This protocol will be administered at weekly sessions of 30 minutes with a period of 3 times / week with a total of 20 sessions, distributed over a 7-week period. They will be evaluated at baseline, after the end of the last treatment session and after two months of follow-up.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control without Electric Stimulation Therapy
Description: The control group continue with their usual conservative and pharmacological treatment and will not receive electrotherapy treatment. They will be evaluated too at baseline, after the end of the last treatment session and after two months of follow-up.
Study: NCT04856644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-month rifapentine-based regimen
Description: 8 weeks of isoniazid, pyrazinamide, rifapentine, and moxifloxacin, followed by 9 weeks of isoniazid, rifapentine and moxifloxacin
Study: NCT04660630

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Gene detection of therapeutic drugs for chronic cardiovascular and cerebrovascular diseases
Description: According to the results of drug gene chip detection, we combined with the clinical characteristics of the patient to choose more suitable cardiovascular and cerebrovascular treatment drugs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular follow-up and patient education
Description: The subjects received regular follow-up and patient education.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular follow-up and patient education
Description: The subjects received regular follow-up and patient education.
Study: NCT00044915

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Repinotan HCl (BAYX3702)
Description: All patients receive 1.25 mg of repinotan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients receive 1.25 mg of placebo
Study: NCT00657059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irbesartan
Description: In the ARB lead-in phase, each subject will be on a strict sodium-restricted diet ( \< 5 g NaCl/day), and then given a stable dose (150mg \~ 300mg/day) of irbesartan (Aprovel) for 3 months until reaching the target blood pressure (BP) level of ≤ 125/75 mmHg. Patients will continue ARB treatment in the drug treatment phase and at lease 3 years in the follow-up phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irbesartan
Description: In the ARB lead-in phase, each subject will be on a strict sodium-restricted diet ( \< 5 g NaCl/day), and then given a stable dose (150mg \~ 300mg/day) of irbesartan (Aprovel) for 3 months until reaching the target blood pressure (BP) level of ≤ 125/75 mmHg. Patients will continue ARB treatment in the drug treatment phase and at lease 3 years in the follow-up phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irbesartan
Description: In the ARB lead-in phase, each subject will be on a strict sodium-restricted diet ( \< 5 g NaCl/day), and then given a stable dose (150mg \~ 300mg/day) of irbesartan (Aprovel) for 3 months until reaching the target blood pressure (BP) level of ≤ 125/75 mmHg. Patients will continue ARB treatment in the drug treatment phase and at lease 3 years in the follow-up phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone (MP) or prednisone (pred)
Description: Patients will take oral Pred ( 0.5 mg/kg/d) on alternate days, and on the first, third and fifth months of the drug treatment phase, patients will be given intravenous pulse therapy with methylprednisolone ( 0.5 g/day) for 3 successive days. And after 6 months, Pred should be tapered to be stopped until the end of the 12-month course of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone (MP) or prednisone (pred)
Description: Patients will take oral Pred ( 0.5 mg/kg/d) on alternate days, and on the first, third and fifth months of the drug treatment phase, patients will be given intravenous pulse therapy with methylprednisolone ( 0.5 g/day) for 3 successive days. And after 6 months, Pred should be tapered to be stopped until the end of the 12-month course of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil (MMF)
Description: Patients will take MMF 1.0g bid (wt ≥ 50kg) or 0.75g bid (wt \< 50kg) for the first 6-month of drug treatment phase, then to 0.5 bid (wt ≥ 50kg) for the remaining 6-month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil (MMF)
Description: Patients will take MMF 1.0g bid (wt ≥ 50kg) or 0.75g bid (wt \< 50kg) for the first 6-month of drug treatment phase, then to 0.5 bid (wt ≥ 50kg) for the remaining 6-month.
Study: NCT02714725

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: During bypass, patients will receive dexmedetomidine infusion 0.5 mcg/kg/hr

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Dexmedetomidine normal saline infusion
Description: During bypass, patients will receive normal saline infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol infusion
Description: During bypass, patients will receive propofol infusion 50 - 70 mcg/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol infusion
Description: During bypass, patients will receive propofol infusion 50 - 70 mcg/kg/min
Study: NCT01486953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Using random numbers, patients were divided into two groups to receive either sevoflurane or desflurane. After induction of anesthesia and intubation, the patient's lungs were ventilated in constant-flow VCV mode by an anesthetic Ventilator (Datex-Ohmeda, GE healthcare, Finland). Ventilator settings were tidal volume 10 ml/kg, inspiratory:expiratory (I:E) ratio 1:1.5, inspired oxygen concentration (FiO2) 0.5 with air, and 3 L/min of inspiratory fresh gas flow. End-inspiratory pause was set 20% of total breathing cycle. Positive end-expiratory pressure (PEEP) was not used. Respiratory rate was adjusted to maintain an end-tidal CO2 pressure of 33-35 mmHg. Patients received desflurane 6-7% for maintenance of anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Using random numbers, patients were divided into two groups to receive either sevoflurane or desflurane. After induction of anesthesia and intubation, the patient's lungs were ventilated in constant-flow VCV mode by an anesthetic Ventilator (Datex-Ohmeda, GE healthcare, Finland). Ventilator settings were tidal volume 10 ml/kg, inspiratory:expiratory (I:E) ratio 1:1.5, inspired oxygen concentration (FiO2) 0.5 with air, and 3 L/min of inspiratory fresh gas flow. End-inspiratory pause was set 20% of total breathing cycle. Positive end-expiratory pressure (PEEP) was not used. Respiratory rate was adjusted to maintain an end-tidal CO2 pressure of 33-35 mmHg. Patients received sevoflurane 2-2.5% for maintenance of anesthesia.
Study: NCT03891303

Intervention type: OTHER
Intervention: Allogenic blood transfusion (ABT)
Description: During elective open aortic surgery, the autologous blood from ICS was processed and re-transfused in all patients. However, TR group additionally received ABT.
Study: NCT00699452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: candesartan
Description: Candesartan 8 mg/d for two weeks, then 16 mg/d until valve replacement surgery (approximately 3 months)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT04385888

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-calorie sweetener restriction
Description: Participants will avoid low-calorie sweetened beverages and other sources of low-calorie sweeteners for 12 weeks and will instead consume unsweetened alternatives, such as still or sparkling water
Study: NCT01557283

Intervention type: OTHER
Intervention: Enbrel treatment
Description: Enbrel SC 50mg once weekly or 25mg twice weekly
Study: NCT02730988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Stable Group
Description: The weight stable control group is monitored bi-weekly by study staff to ensure weight stability over the course of the study. During group sessions, participants are weighed and encouraged to maintain weight within ±5% of baseline. They also receive non-weight loss health related topics presented by study staff. If participants attend 75% of the educational sessions, all baseline and follow-up testing sessions, and maintain weight stability over the course of the study (defined as less than a 5% differential between weight measured at week 0 and 24), they will be eligible to receive up to 3 months of Medifast MRPs along with a 30-60 minute RD-led dietary instruction session on how to follow the Medifast 4 \& 2 \& 1 Plan.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Stable Group
Description: The weight stable control group is monitored bi-weekly by study staff to ensure weight stability over the course of the study. During group sessions, participants are weighed and encouraged to maintain weight within ±5% of baseline. They also receive non-weight loss health related topics presented by study staff. If participants attend 75% of the educational sessions, all baseline and follow-up testing sessions, and maintain weight stability over the course of the study (defined as less than a 5% differential between weight measured at week 0 and 24), they will be eligible to receive up to 3 months of Medifast MRPs along with a 30-60 minute RD-led dietary instruction session on how to follow the Medifast 4 \& 2 \& 1 Plan.
Study: NCT00861263

Intervention type: DEVICE
Group type: OTHER
Intervention: overtube use during enteroscopy
Description: use of overtube for the regular scheduled enteroscopy
Study: NCT01377077

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: punchgrafting
Description: autologous skin transplantation of small skinbiopsies taken from the hip and replaced in the depigmented lesions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: punchgrafting
Description: autologous skin transplantation of small skinbiopsies taken from the hip and replaced in the depigmented lesions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: punchgrafting
Description: autologous skin transplantation of small skinbiopsies taken from the hip and replaced in the depigmented lesions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: punchgrafting
Description: autologous skingrafting of small skin biopsies taken from the hip en placed in the depigmented lesions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: punchgrafting
Description: autologous skingrafting of small skin biopsies taken from the hip en placed in the depigmented lesions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: punchgrafting
Description: autologous skingrafting of small skin biopsies taken from the hip en placed in the depigmented lesions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: punchgrafting
Description: autologous skingrafting of small skin biopsies taken from the hip en placed in the depigmented lesions
Study: NCT05031169

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interdental papilla surgical reconstructiion
Description: Surgical treatment of receding interdentalpapillae

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interdental papilla surgical reconstructiion
Description: Surgical treatment of receding interdentalpapillae
Study: NCT00519961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elecsys®proBNP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elecsys®proBNP
Study: NCT01616433

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AFEP
Description: Arthritis Foundation Exercise Program (10 weeks, twice a week, 60 minutes per session)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 Keys to Healthy Aging
Description: 10 Keys to Healthy Aging. 10 week program, twice a week, 75 minutes per session.
Study: NCT03527914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal Based Outcomes
Description: Up to three goals can be tracked during treatment, although patients often decide to just focus on one. Progress on the goal is then quantitatively rated by the patient, with the provider, at every appointment. Adjustments in the care are then made in an iterative process to ensure that the goal will be met.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Patients will receive their standard care at the Outpatient Mental Health Service
Study: NCT02579707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG120
Description: AG120 in fed and fasted conditions. Part 2- AG120 single dose exposure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AG120
Description: AG120 in fed and fasted conditions. Part 2- AG120 single dose exposure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AG120
Description: AG120 in fed and fasted conditions. Part 2- AG120 single dose exposure
Study: NCT00036686

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy protein isolate
Description: Arm I: Patients receive oral soy protein isolate twice daily and oral multivitamins once daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Arm II: Patients receive oral placebo twice daily and oral multivitamins once daily.